Constellation Pharmaceuticals Selected by AlwaysOn as an OnDC Top 100 Winner

Recognized for Leading Innovation in Biotechnology
CAMBRIDGE, Mass.--(Business Wire)--
Constellation Pharmaceuticals, Inc., the leading biopharmaceutical company
focused on discovering and developing new drugs targeting epigenetic regulation
of the human genome, today announced that it has been chosen by AlwaysOn as one
of the OnDC Top 100 Winners. Inclusion in the OnDC 100 signifies major
developments in the creation of new business opportunities that contribute to
the renewed and continued prosperity of our country. Constellation
Pharmaceuticals was specially selected by the AlwaysOn editorial team and
industry experts spanning the globe based on a set of five criteria: innovation,
market potential, commercialization, stakeholder value, and media buzz.

"It`s no secret that technology and innovation are vital to bringing our country
out of economic recession and transforming important sectors like energy and
healthcare," said Tony Perkins, founder and CEO of AlwaysOn. "We congratulate
the OnDC 100 for their success in introducing new tools, services, and systems
to address the nation`s top priorities."

"Being selected as one of the top OnDC winners is an honor that highlights
Constellation`s potential to make a significant impact for patients through
epigenetics, the next biological breakthrough offering promise for targeting
disease above and beyond the genome," said Mark A. Goldsmith, M.D., Ph.D., Chief
Executive Officer of Constellation Pharmaceuticals. "We have built a world-class
team as evidenced by the recent hiring of Ed Harlow, a leading cancer biologist,
as our Chief Scientific Officer. With our strong scientific team and innovative
product engine we should continue making great progress toward discovering a new
class of drugs that ameliorate human disease by modulating the epigenome."

The OnDC 100 winners were selected from among hundreds of other technology
companies nominated by investors, bankers, journalists and industry insiders.
The AlwaysOn editorial team conducted a rigorous three-month selection process
to finalize the 2009 list.

Constellation Pharmaceuticals is the leading biopharmaceutical company dedicated
to the discovery and development of novel drugs targeting selective regulators
of epigenetic function. The company raised a $32 million Series A financing and
is currently building a preclinical pipeline of epigenetic drugs.

Epigenetics is an exciting new field of biology that involves chemical
modifications of both DNA and of its packaging proteins ("chromatin"), which are
collectively called the `epigenome.` The genome, or DNA, is the "blueprint" for
the human body, consisting of thousands of genes, which are the fundamental
units of information necessary for normal cell growth and development. In
contrast, the epigenome plays a critical role in regulating the expression of
genes, that is, switching genes on or off - or in the case of disease, for
switching genes on or off incorrectly. This new field of Epigenetic science
provides the opportunity to create a broad new class of human therapeutics
targeting selective regulators of epigenetic function.

Constellation Pharmaceuticals and the OnDC Top 100 Companies will be honored at
AlwaysOn`s OnDC event on October 19th-21st at the Four Seasons Hotel in
Washington DC. This two-and-a-half-day executive event features CEO
presentations and high-level debates on sectors most impacted by the federal
government including greentech, on-demand computing and IT security, education,
and the life sciences.

A full list of all the OnDC Top 100 Winners can be found on the AlwaysOn Web
site at http://alwayson.goingon.com/permalink/post/33638.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is the leading biopharmaceutical company dedicated
to the development of novel therapeutics in the emerging field of Epigenetics, a
new field of science that focuses on selective regulators of gene function and
expression. Constellation`s initial focus is in oncology, and the Company`s
platform will also be applicable to other therapeutic areas including
autoimmune, inflammatory and neurological diseases. The Company`s academic
founders represent the core thought leaders in epigenetics responsible for key
advances, insights and discoveries in the field. Constellation Pharmaceuticals
is located in Cambridge, Massachusetts. For more information, please visit the
company's website at www.constellationpharma.com.

About AlwaysOn

AlwaysOn ignited the open-media revolution in early 2003 by being the first
media brand to launch a global blog network. In 2004, AlwaysOn continued to lead
the media industry in innovation by introducing a social network where members
can connect and engage. AlwaysOn is also revolutionizing the media business by
applying its open-media principles to its executive event series (Summit at
Stanford, OnMedia, OnHollywood, OnDC, GoingGreen East and West, Venture Summit
East and West) and quarterly print "blogozine" by empowering its members to post
and share their ideas and meet each other online. As our loyal readers know,
AlwaysOn is committed to the free-market, merit-driven approach to reporting and
event programming. No other media brand has dared to create such open
interaction with its readers and event participants.

For Constellation Pharmaceuticals
Adriana Jenkins, 617-744-1713
adrianajenkins@gmail.com

Copyright Business Wire 2009